- Generalized anxiety disorder (GAD) is intense, long-lasting worry (6+ months) that disrupts daily life.
- Symptoms are physical (tension, insomnia, rapid heartbeat) and psychological (catastrophic thinking, irritability).
- Causes include neurotransmitter imbalance (serotonin, GABA), personality traits, chronic stress and substances.
- Psychotherapy and lifestyle change beat drugs long-term; prescription sedatives carry dependence/withdrawal risks.
What is generalized anxiety disorder?
An anxiety disorder is a psychological state in which a person constantly feels anxious, with physical and/or psychological symptoms. Generalized anxiety disorder (GAD) is one type, in which the anxiety is intense and long-lasting — a person experiences continuous worry about work, family, relationships or other areas of life. Other types of anxiety disorder include panic disorder, social anxiety disorder, recurrent anxiety or panic attacks, specific phobia, and agoraphobia.
Symptoms
An anxiety disorder can present with various physical symptoms: muscle tension and stiffness, nausea or stomach discomfort, cold sweaty hands, frequent urination or diarrhoea, insomnia or disturbed sleep, dry mouth or difficulty swallowing, and chest pain or discomfort. Alongside physical tension, it can also bring psychological symptoms: catastrophic thinking, difficulty concentrating, excessive fear, irritability and obsessive behaviour.
Causes
A chemical imbalance in the brain can contribute — a disturbed balance of neurotransmitters such as serotonin and GABA. Certain personality traits, such as perfectionism, shyness or excessive self-criticism, can increase the tendency toward GAD. Constant stress load — financial difficulties, relationship problems, work-related stress or significant life changes — can trigger or intensify symptoms. Chronic health conditions, especially those involving pain, can raise anxiety risk. Substances such as drugs, alcohol or excessive caffeine can also cause or intensify symptoms.
Treatment
One form of treatment is psychological therapy, which helps a person recognise and understand the sources of their anxiety and learn to manage and reduce it. Prescription medications may also be prescribed. However, prescription anxiety drugs can have several drawbacks: dependence risk (some, such as benzodiazepines, cause dependence with longer use); side effects (dizziness, drowsiness, impaired cognition); only temporary relief (they relieve symptoms but do not remove the underlying causes); tolerance (larger doses may be needed over time); withdrawal symptoms; masking of underlying issues; and interactions with other medications. For this reason, if there is no alternative, prescription anxiety drugs are recommended for short-term use — discuss this with your doctor.
Lifestyle and what we can change
Stress management is one way to reduce anxiety. Interestingly, television viewing strongly affects the brain and can provoke anxiety in some people, through information overload, negative content (violence, crime, disasters), social comparison and insecurity, a sedentary lifestyle, disturbed sleep, and constant stimulation that keeps the brain in a heightened state of alertness. Non-prescription support such as the flavonoid vitexin is studied as a complementary approach for anxiety — the quality of the active compound matters greatly for results. Seek professional support where appropriate.
Prescription sedatives carry dependence and withdrawal risks. Vitexin is studied for acting on GABA-A as a modulator, examined as complementary support.
Vitexin 90 by Zenius Labs™ →GAD is a mental-health condition marked by constant worry about everyday situations — work, family, relationships, health. It lasts longer than 6 months and significantly disrupts daily life.
Physical: rapid heartbeat, muscle tension, trembling, headache, insomnia, fatigue. Psychological: catastrophic thinking, difficulty concentrating, excessive fear, irritability, obsessive behaviour.
Not always. Prescription benzodiazepines act quickly but can cause dependence, tolerance and withdrawal. Psychotherapy and lifestyle change are a more effective long-term strategy. Natural supplements that act on GABA receptors without dependence risk are studied as complementary support. Discuss options with a professional.
Yes. Stress management, better sleep, reduced caffeine/alcohol, physical activity, and limiting overstimulation (including heavy TV viewing) all help. Addressing the cause is more effective long-term than masking symptoms.
- Saquib J et al. Social media use and mental health. Makü İİBF Dergisi. 2019. dergipark.org.tr
- Velasquez ACA et al. Effects of Passiflora incarnata and Valeriana officinalis in the control of anxiety due to tooth extraction: a randomized controlled clinical trial. Oral and maxillofacial surgery. 2024. PubMed
- Miyasaka LS et al. Passiflora for anxiety disorder. The Cochrane database of systematic reviews. 2007. PubMed
- Wolfman C et al. Possible anxiolytic effects of chrysin, a central benzodiazepine receptor ligand isolated from Passiflora coerulea. Pharmacology, biochemistry, and behavior. 1994. PubMed
- Krenn L [Passion Flower (Passiflora incarnata L.)–a reliable herbal sedative]. Wiener medizinische Wochenschrift (1946). 2002. PubMed
- Medina JH et al. Chrysin (5,7-di-OH-flavone), a naturally-occurring ligand for benzodiazepine receptors, with anticonvulsant properties. Biochemical pharmacology. 1990. PubMed
- Al Hasan MS et al. Assessment of sedative activity of Chrysin: Behavioral approach with pharmacokinetics, toxicological profile and molecular docking. Sleep medicine. 2025. PubMed
- Nagano M et al. Reduction of depression and anxiety by 4 weeks Hericium erinaceus intake. Biomedical research (Tokyo, Japan). 2010. PubMed
- Vigna L et al. Hericium erinaceus Improves Mood and Sleep Disorders in Patients Affected by Overweight or Obesity: Could Circulating Pro-BDNF and BDNF Be Potential Biomarkers?. Evidence-based complementary and alternative medicine : eCAM. 2019. PubMed
- Koszła O et al. Biotransformation of Ganoderma lucidum and Hericium erinaceus for ex vivo gut-brain axis modulation and mood-related outcomes in humans: CREB/BDNF signaling and microbiota-driven synergies. Journal of ethnopharmacology. 2025. PubMed
- Mori K et al. Nerve growth factor-inducing activity of Hericium erinaceus in 1321N1 human astrocytoma cells. Biological & pharmaceutical bulletin. 2008. PubMed
- Lai PL et al. Neurotrophic properties of the Lion’s mane medicinal mushroom, Hericium erinaceus (Higher Basidiomycetes) from Malaysia. International journal of medicinal mushrooms. 2013. PubMed
- Cipriano GL et al. Beyond Neurotrophins: A Proposed Neurotrophic-Epigenetic Axis Mediated by Non-Coding RNA Networks for Hericium erinaceus Bioactives-A Hypothesis-Driven Review. International journal of molecular sciences. 2026. PubMed
- Roda E et al. Cognitive Healthy Aging in Mice: Boosting Memory by an Ergothioneine-Rich Hericium erinaceus Primordium Extract. Biology. 2023. PubMed
- Ratto D et al. Hericium erinaceus Improves Recognition Memory and Induces Hippocampal and Cerebellar Neurogenesis in Frail Mice during Aging. Nutrients. 2019. PubMed
- Priori EC et al. Hericium erinaceus Extract Exerts Beneficial Effects on Gut-Neuroinflammaging-Cognitive Axis in Elderly Mice. Biology. 2023. PubMed
- Jeanclos E et al. Improved cognition, mild anxiety-like behavior and decreased motor performance in pyridoxal phosphatase-deficient mice. Biochimica et biophysica acta. Molecular basis of disease. 2019. PubMed
- Kasaragod VB et al. Pyridoxal kinase inhibition by artemisinins down-regulates inhibitory neurotransmission. Proceedings of the National Academy of Sciences of the United States of America. 2020. PubMed
- Singhuber J et al. GABA(A) receptor modulators from Chinese herbal medicines traditionally applied against insomnia and anxiety. Phytomedicine : international journal of phytotherapy and phytopharmacology. 2012. PubMed
- Evans AK et al. Pharmacology of the beta-carboline FG-7,142, a partial inverse agonist at the benzodiazepine allosteric site of the GABA A receptor: neurochemical, neurophysiological, and behavioral effects. CNS drug reviews. 2007. PubMed
- Zhong H et al. Neonatal inflammation via persistent TGF-β1 downregulation decreases GABA(A)R expression in basolateral amygdala leading to the imbalance of the local excitation-inhibition circuits and anxiety-like phenotype in adult mice. Neurobiology of disease. 2022. PubMed
- Pétursson H The benzodiazepine withdrawal syndrome. Addiction (Abingdon, England). 1994. PubMed
- Soyka M Treatment of Benzodiazepine Dependence. The New England journal of medicine. 2017. PubMed
- O’brien CP Benzodiazepine use, abuse, and dependence. The Journal of clinical psychiatry. 2005. PubMed
- Akhondzadeh S et al. Passionflower in the treatment of generalized anxiety: a pilot double-blind randomized controlled trial with oxazepam. Journal of clinical pharmacy and therapeutics. 2001. PubMed
- Stein MB Neurobiology of generalized anxiety disorder. The Journal of clinical psychiatry. 2009. PubMed
- Pollack MH Refractory generalized anxiety disorder. The Journal of clinical psychiatry. 2009. PubMed
- Richier C et al. Brain Age Prediction in Generalized Anxiety Disorder using a Convolutional Neural Network. Research square. 2025. PubMed
- Amigó J et al. The absence of 5-HT(4) receptors modulates depression- and anxiety-like responses and influences the response of fluoxetine in olfactory bulbectomised mice: Adaptive changes in hippocampal neuroplasticity markers and 5-HT(1A) autoreceptor. Neuropharmacology. 2016. PubMed
- Paliokha R et al. Effects of pre-gestational exposure to the stressors and perinatal mirtazapine administration on the excitability of hippocampal glutamate and brainstem monoaminergic neurons, hippocampal neuroplasticity, and anxiety-like behavior in rats. Molecular psychiatry. 2026. PubMed
- Cryan JF et al. The Microbiota-Gut-Brain Axis. Physiological reviews. 2019. PubMed
- Rutsch A et al. The Gut-Brain Axis: How Microbiota and Host Inflammasome Influence Brain Physiology and Pathology. Frontiers in immunology. 2020. PubMed
- Foster JA et al. Stress & the gut-brain axis: Regulation by the microbiome. Neurobiology of stress. 2017. PubMed
- Bear T et al. The Microbiome-Gut-Brain Axis and Resilience to Developing Anxiety or Depression under Stress. Microorganisms. 2021. PubMed